（文章来源：证券日报） 证券日报网讯 12月11日，益盛药业在互动平台回答投资者提问时表示，截至2025年12月10日，公司股 东总户数为27186户。 ...

Core Viewpoint - The stock market showed a decline on December 3, with the Shanghai Composite Index down by 0.51%, the Shenzhen Component Index down by 0.78%, and the ChiNext Index down by 1.12% [1]. Group 1: Trading Volume and Activity - A total of 2,574 stocks saw an increase in average trading volume, with 72 stocks experiencing a rise of over 50% [1]. - Notable stocks with significant increases in average trading volume include Shuangqiang Technology (up 390.83%), Chuhuan Technology (up 389.04%), and Huitian Thermal Power (up 352.37%) [1]. - In terms of trading activity, Tongyu Communications, ST Qibu, and Daoming Optics had the highest increases in trading counts, indicating active performance [1]. Group 2: Stocks with Significant Increases - The following stocks had both average trading volume and trading counts increase by over 50%: Huayang New Materials, Suqian Liansheng, and Xinke Materials [3][4]. - Huayang New Materials reported a daily increase of 10.07% with an average trading volume of 2,388 shares, and trading counts increased by 153.71% [3]. - Suqian Liansheng had a daily increase of 6.21% with an average trading volume of 1,453 shares, and trading counts surged by 333.31% [4].

Market Overview - The market experienced fluctuations with the ChiNext Index dropping over 1% and a total transaction volume of 1.68 trillion [1] - The superhard materials sector showed resilience, with Huanghe Xuanfeng hitting the daily limit and Sifangda rising over 10% [1] - The coal sector saw collective gains, with companies like Dayou Energy and Antai Group reaching the daily limit [1] - The flu prevention concept was active, with Yisheng Pharmaceutical hitting the daily limit and Yue Wannianqing rising over 10% [1] - Overall, more stocks declined than rose, with over 3,800 stocks in the Shanghai, Shenzhen, and Beijing markets in the red [1] Hot Topics Cultivated Diamonds - The cultivated diamond sector surged, with Huanghe Xuanfeng and Guoji Heavy Industry hitting the daily limit, and Sifangda increasing by 15% [4] - The demand for diamond as a heat dissipation material is expected to grow significantly due to advancements in semiconductor technology [5] - The diamond heat dissipation market is projected to expand from $0.37 million in 2025 to $15.2 billion by 2030, indicating explosive growth [6] Coal Sector - The coal sector performed well, with Antai Group achieving two consecutive daily limits and companies like Huitian Thermal Power and New Dazhou A also hitting the daily limit [7] - A cold wave affecting central and eastern China has led to significant temperature drops, boosting energy procurement demand [7] - Analysts expect coal prices to maintain upward momentum due to stricter safety regulations and increased demand during the winter heating season [8] Pharmaceutical Sector - The pharmaceutical sector was active again, with Haiwang Biological achieving six consecutive daily limits and companies like Ruikang Pharmaceutical and Yisheng Pharmaceutical hitting the daily limit [9] - The high transmissibility of the flu virus has created a surge in demand for antiviral medications and related products [10] - Retail pharmacies are expected to benefit from increased demand for protective products such as masks and disinfectants [10]

Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

Group 1 - The flu-related concept stocks experienced significant fluctuations, with Yingke Group hitting the daily limit up [1] - Haiwang Bio and Yisheng Pharmaceutical also reached the daily limit up, indicating strong market interest [1] - Yue Wannianqing saw an increase of over 10%, while companies like Guangji Pharmaceutical, Panlong Pharmaceutical, and Jindike also experienced gains [1]

Group 1 - Yisheng Pharmaceutical's stock price fell by 5.12% on November 21, closing at 7.79 yuan per share, with a trading volume of 51.63 million yuan and a turnover rate of 2.79%, resulting in a total market capitalization of 2.578 billion yuan [1] - The stock has experienced a continuous decline for four consecutive days, with a cumulative drop of 4.98% during this period [1] - Yisheng Pharmaceutical, established on June 11, 1997, and listed on March 18, 2011, specializes in the research, production, and sales of traditional Chinese medicine, with its main revenue sources being capsule products (47.89%), injection products (30.94%), cosmetics (7.39%), ginseng products (6.89%), other products (6.59%), and bee products (0.31%) [1] Group 2 - Among the top ten circulating shareholders of Yisheng Pharmaceutical, a fund under Nuoan Fund, specifically Nuoan Multi-Strategy Mixed A (320016), entered the top ten in the third quarter, holding 1.9863 million shares, which accounts for 0.86% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 834,200 yuan, with a total floating loss of 854,100 yuan during the four-day decline [2] - Nuoan Multi-Strategy Mixed A was established on August 9, 2011, with a current scale of 1.855 billion yuan, achieving a year-to-date return of 73.37% and ranking 205 out of 8,136 in its category [2]

Core Viewpoint - Yisheng Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.66% but a recent decline of 2.12% over the past five trading days [1][2]. Financial Performance - For the period from January to September 2025, Yisheng Pharmaceutical reported a revenue of 476 million yuan, representing a year-on-year decrease of 5.81%. The net profit attributable to shareholders was 24.13 million yuan, down 32.72% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 213 million yuan, with 99.29 million yuan distributed over the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Yisheng Pharmaceutical was 19,700, a decrease of 1.92% from the previous period. The average number of circulating shares per person increased by 1.96% to 11,740 shares [2]. - Notably, as of September 30, 2025, the eighth largest circulating shareholder is the Nuoan Multi-Strategy Mixed A fund, which holds 1.9863 million shares as a new shareholder [3]. Stock Performance - As of November 19, Yisheng Pharmaceutical's stock price was 8.31 yuan per share, with a market capitalization of 2.75 billion yuan. The stock saw a trading volume of 12.1 million yuan and a turnover rate of 0.62% [1].

Meeting Overview - The first temporary shareholders' meeting of Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. was held on November 12, 2025, at 14:30 [4][5] - The meeting was conducted through a combination of on-site voting and online voting [3][6] Attendance - A total of 72 shareholders attended the meeting, representing 135,423,848 shares, which is 40.9195% of the total shares [9] - Among them, 67 shareholders participated via online voting, representing 2,682,500 shares, or 0.8105% of the total shares [9] Resolutions Passed - The meeting approved several key resolutions, including: 1. **Application for Working Capital Loan**: Approved with 98.2932% in favor [11] 2. **Cancellation of Supervisory Board and Amendment of Articles of Association**: Approved with 98.2932% in favor [12] 3. **Amendments to Governance Systems**: Multiple amendments were approved, including: - **Amendment of Shareholders' Meeting Rules**: Approved with 98.3014% in favor [15] - **Amendment of Board Meeting Rules**: Approved with 98.3014% in favor [17] - **Amendment of Independent Director Work System**: Approved with 98.3014% in favor [19] - **Amendment of External Investment Management System**: Approved with 98.3014% in favor [20] - **Amendment of Related Party Transaction Management Measures**: Approved with 98.2977% in favor [21] - **Amendment of Fundraising Management Measures**: Approved with 98.2944% in favor [22] - **Amendment of Financing and External Guarantee Management Measures**: Approved with 98.2944% in favor [23] - **Establishment of Director and Senior Management Compensation Management System**: Approved with 98.2828% in favor [24] - **Amendment of Cumulative Voting Implementation Rules**: Approved with 98.2965% in favor [25] Legal Opinion - The meeting was witnessed by lawyers from Beijing Zhide Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [26] Documents for Reference - The resolutions from the first temporary shareholders' meeting and the legal opinion from Beijing Zhide Law Firm are available for review [27]

Core Points - Yisheng Pharmaceutical announced the election of Tong Xiaole as the employee representative director of the ninth board of directors during the second employee representative conference held on November 12, 2025 [1] Group 1 - The company held its second employee representative conference on November 12, 2025 [1] - The proposal to elect the employee representative director was reviewed and approved by the attending employee representatives [1] - Tong Xiaole was elected to serve as the employee representative director on the ninth board of directors [1]

证券代码：002566 证券简称：益盛药业 公告编号：2025-050 吉林省集安益盛药业股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议的情形。 3、本次股东会采用现场表决、网络投票相结合的方式。 一、会议召开情况 1、召开时间： 现场会议时间：2025年11月12日（星期三）下午14:30。 网络投票时间为：2025年11月12日，其中：通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年11月15日上午9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票的具体时间为2025年11月12日 9:15-15:00期间的任意时间。 2、召开地点：吉林省集安市文化东路17－20号公司四楼会议室。 3、召开方式：本次股东会采用现场表决、网络投票相结合的方式。 4、召集人：吉林省集安益盛药业股份有限公司董事会。 5、主持人：董事长张益胜先生。 6、本次股东会议的召开符 ...